Clinical Trial Update: Complement C5 mAb in the Treatment of Anti-GBM Disease [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a Complement C5 monoclonal antibody for anti-glomerular basement membrane disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anti-glomerular Basement Membrane Disease

Drugs mentioned

• Complement C5 monoclonal antibody

Snippet

Sponsor: Peking University First Hospital | Conditions: Autoimmune Diseases | Phase 2 | Status: COMPLETED